Characterization of SARS-CoV-2-specific antibodies in COVID-19 patients reveals highly potent neutralizing IgA  

作　　者：Weihong Zeng Huan Ma Chengchao Ding Yunru Yang Yong Sun Xiaoxue Huang Weihuang He Yan Xiang Yong Gao Tengchuan Jin 

机构地区：[1]Division of Life Sciences and Medicine,Department of Obstetrics and Gynecology,The First Afliated Hospital of USTC,University of Science and Technology of China,Hefei,Anhui,China [2]Hefei National Laboratory for Physical Sciences at Microscale,CAS Key Laboratory of Innate Immunity and Chronic Disease,Division of Life Sciences and Medicine,School of Basic Medical Sciences,University of Science and Technology of China,Hefei,Anhui,China [3]Division of Life Sciences and Medicine,Department of Pulmonary and Critical Care Medicine,The First Affliated Hospital of USTC,University of Science and Technology of China,Hefei,Anhui,China [4]Division of Life Sciences and Medicine,Department of Infectious Diseases,The First Affliated Hospital of USTC,University of Science and Technology of China,Hefei,Anhui,China [5]Anhui Center for Disease Control and Prevention(Anhui CDC),Hefei,Anhui,China [6]Kangrun Biotech LTD,Guangzhou,Guangdong,China [7]Department of Microbiology,Immunology and Molecular Genetics,University of Texas Health Science Center at San Antonio,San Antonio,TX,USA [8]CAS Center for Excellence in Molecular Cell Science,Chinese Academy of Science,Shanghai,China

出　　处：《Signal Transduction and Targeted Therapy》2021年第2期254-256,共3页信号转导与靶向治疗（英文）

基　　金：This work was supported by grants from the Strategic Priority Research Program of the Chinese Academy of Sciences(XDB29030104);National Natural Science Fund(31870731,31971129 and U1732109);the Fundamental Research Funds for the Central Universities,the new medical science fund of USTC,COVID-19 special task grants supported by Chinese Academy of Science Clinical Research Hospital(Hefei)with Grant Nos.YD2070002017 and YD2070002001,respectively.

摘　　要：Dear Editor,The coronavirus disease 2019(COVID-19),caused by the Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2),is an ongoing threat to public health.Due to the presence of neutralizing antibodies in convalescent patients,convalescent plasma transfusion has been tested as a promising therapy for severe COVID-19 patients.12 We and others previously found a surprisingly early serum lgA antibody response in the COVID-19 patients.However,the relative contribution of the lgA antibody towards virus neutralization with respect to other antibody isotypes is unknown.

关 键 词：PATIENTS ANTIBODIES TRANSFUSION 

分 类 号：R563.1[医药卫生—呼吸系统]